Earnings Reports
Filter News
Found 90,548 articles
-
Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections
3/18/2024
Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the full year of 2023 and provided an update on progress toward achieving key corporate objectives.
-
Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
3/18/2024
Biora Therapeutics, Inc today announced it will report financial results and provide a corporate update for the fourth quarter and full year ended December 31, 2023.
-
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results
3/18/2024
Exagen Inc. today reported financial results for the fourth quarter and full year ended December 31, 2023.
-
Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights
3/18/2024
Tango Therapeutics, Inc., a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the fourth quarter and full year ended December 31, 2023, and provided business highlights.
-
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
3/18/2024
Acurx Pharmaceuticals, Inc. announced certain financial and operational results for the fourth quarter and full year ended December 31, 2023.
-
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
3/18/2024
Leap Therapeutics, Inc., a biotechnology company focused on developing targeted and immuno-oncology therapeutics, reported financial results for the fourth quarter and year ended December 31, 2023.
-
Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023
3/18/2024
Daxor Corporation, the global leader in blood volume measurement technology, announces the filing of its Annual Report to Shareholders on Form N-CSR, disclosing its schedule of portfolio holdings as of December 31, 2023.
-
Nanox to Report Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024
3/18/2024
NANO-X IMAGING LTD today announced that it will report its financial results for the quarter and fiscal year ended December 31, 2023, before market open on Monday, April 1, 2024.
-
Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress
3/18/2024
Oculis Holding AG, a global biopharmaceutical company purposefully driven to save sight and improve eye care, announced fourth quarter and full year financial results for the period ended December 31, 2023, and an overview of the Company’s progress.
-
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
3/18/2024
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the full year 2023 and provided a business update.
-
Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024
3/18/2024
Zevra Therapeutics, Inc. today announced that it will host a conference call and live audio webcast on Thursday, March 28, 2024, at 4:30 p.m. ET, to review its corporate and financial results for the fourth quarter and full year 2023.
-
Humacyte to Present 2023 Fourth Quarter and Year-End Financial Results and Provide Corporate Update on March 22, 2024
3/18/2024
Humacyte, Inc. will release its financial results for the fourth quarter and year ended December 31, 2023, on Friday, March 22, 2024.
-
Medigene AG to report full year 2023 financial results on March 28, 2024
3/18/2024
Medigene AG will report financial results and provide a corporate update for the fiscal year ended December 31, 2023, on Thursday, March 28, 2024.
-
Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
3/18/2024
Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company, today announced its financial and operating results for the fourth quarter and full-year ended December 31, 2023.
-
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
3/18/2024
Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.
-
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
3/18/2024
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the fourth quarter and full year 2023.
-
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
3/18/2024
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate highlights for the year ended December 31, 2023.
-
Singular Genomics Reports Recent Highlights and Fourth Quarter and Full Year 2023 Financial Results
3/18/2024
Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the fourth quarter and full year ended December 31, 2023.
-
Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
3/18/2024
Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and experiences, today reported its financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.
-
Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update
3/18/2024
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its 2023 results and provided a business update.